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Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by loss of memory and
cognitive function. A key neuropathological event in AD is the accumulation of amyloid-β (Aβ) peptide. The
production and clearance of Aβ in the brain are regulated by a large group of genes. The expression levels of
these genes must be fine-tuned in the brain to keep Aβ at a balanced amount under physiological condition.
Misregulation of AD genes has been found to either increase AD risk or accelerate the disease progression. In
recent years, important progress has been made in uncovering the regulatory elements and transcriptional factors
that guide the expression of these genes. In this review, we describe the mechanisms of transcriptional regulation
for the known AD genes and the misregualtion that leads to AD susceptibility.
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Alzheimer’s disease (AD) is an age-associated neurodegen-
erative disease and is the most common form of dementia
in the elderly. Like many other geriatric disorders, AD
appears to be multifactorial in its origin. Mounting evi-
dence from genetic, pathological, and functional studies
has shown accumulation of amyloid-β (Aβ) peptide in the
aging brain [1,2]. Aβ aggregates in the forms of soluble Aβ
oligomers and amyloid plaques trigger numerous patho-
physiological changes that ultimately lead to cognitive
dysfunction [3-5]. Aβ is a 40–42 amino-acid peptide that
is generated through multiple proteolytic cleavages of
the amyloid-β protein precursor (APP) [6]. The ‘amyloid
hypothesis’ postulates Aβ as the common initiating factor
in AD pathogenesis and thus places Aβ as the hot research
focus in the past two decades [2]. Emerging evidences
have indicated that an imbalance between production and
clearance of Aβ in the brain leads to AD pathogenesis [3].
A large group of genes have been described to affect Aβ
generation or clearance, which are part of the ‘AD genes’.
Although it is clear that expression levels of AD genes
are important in AD etiology, much remains unknown
about their specific regulation [7]. Studying the regulatory* Correspondence: chenxf@xmu.edu.cn; Bu.Guojun@mayo.edu
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stated.elements of disease genes and their corresponding tran-
scription factors is therefore critically important for eluci-
dation of the disease processes [8]. This review will discuss
the mechanisms of transcriptional regulation for AD genes,
and the misregulation that leads to AD susceptibility.Transcription regulation of BACE1
Aβ is derived from sequential cleavage of APP by β- and
γ-secretase [9]. The initiation of Aβ production by BACE1
and the disease-associated increase of BACE1 level places
BACE1 in the central role of AD pathogenesis [10-13].
Numerous efforts have been devoted to inhibiting BACE1
expression and activity to reduce Aβ production and its
associated neuronal toxicity [14]. BACE1 is an aspartyl
protease which cleaves APP at the known β-secretase sites
of Asp + 1 and Glu + 11 of Aβ [15]. BACE1 knockout mice
do not produce Aβ and are free from AD-associated path-
ologies including memory deficits and neuronal loss
[16,17]. However, detailed studies revealed specific behav-
ioral and physiological alterations in the complete absence
of BACE1 [18-20]. It was suggested that non-APP sub-
strates that are subjected to BACE1 cleavage might be
important for these specific behavioral and functional
changes in BACE1-deficient mice [9].
The BACE1 gene spans about 30 kilobases (kb) on
chromosome 11q23.2 and includes nine exons [14]. Ever
since it was first cloned in 2003, the BACE1 gene promotertd. This is an Open Access article distributed under the terms of the Creative
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the typical CAAT and TATA boxes but has a very high GC
content at its proximal region [21]. The first 600 bp of the
promoter is highly conserved amongst rat, mouse and
human, suggesting that this region contains important
regulatory elements which modulate BACE1 transcrip-
tional activity [21]. A large amount of evidence shows that
the BACE1 promoter contains multiple transcription fac-
tor-binding sites and is typical of an inducible expression
[14,21,22]. A number of transcription factors have been
suggested to control BACE1 transcription, including spe-
cificity protein 1 (SP1), NF-κB, hypoxia inducible factor
1α (HIF-1α), and peroxisome proliferator-activated recep-
tor-gamma (PPAR γ), amongst others.
Sp1 belongs to the Sp/KLF (Specificity protein/Krüppel-
like factor) family and is amongst the first transcription
factor identified to regulate BACE1 gene expression
[23,24]. Deletion analysis of BACE1 promoter and the gel
shifting assay demonstrated the functional binding site for
Sp1 on the BACE1 promoter. Subsequently, Sp1 over-
expression potentiated the activity of the wild-type, but
not of the Sp1-binding-site-mutant BACE1 promoter,
demonstrating an activator function for Sp1 in BACE1
expression. Furthermore, the lack of endogenous Sp1
protein in Sp1-knockout cells markedly reduces BACE1
promoter activity. These results clearly show that Sp1 mod-
ulates the endogenous BACE1 expression [24]. The crucial
role of Sp1 in regulation of BACE1 expression was sup-
ported by different experimental approaches. Mithramycin
A, which inhibits Sp1 binding to DNA, reduced BACE1
expression in a dose-dependent manner [24,25]. 12/15-
Lipoxygenase (12/15-LO), an enzyme widely distributed in
the central nervous system, elevated the levels of BACE1
mRNA and protein through a Sp1-mediated transcription
control [26]. Considering the activation role of Sp1 for
BACE1 expression, future studies are need to illustrate the
spatial and temporal expression patterns, and the transcrip-
tional activity of Sp1 in distinct cell types of the brain.
Importantly, Sp1 is known to interact with NF-kB which
also regulates BACE1 expression level, it remains to be
determined whether they regulate BACE1 gene expression
in a synergistic manner [27,28].
NF-κB is a unique transcription factor that regulates
BACE1 transcription in a cell type-specific manner [29].
A detailed analysis using BACE1 promoter constructs
revealed that NF-κB acts as a repressor for BACE1 tran-
scription in differentiated neuronal cultures and non-
activated glial cultures, but as an activator for BACE1
transcription in activated astrocytic and Aβ-exposed neur-
onal cultures. The effects of NF-κB on the regulation of
BACE1 transcription are mediated by the binding of
distinct NF-κB subunits. The p50/c-Rel heterodimer acts
as repressor, while p50/p65, p52/c-Rel or p52/p65 acts as
activator when binding to BACE1 promoter-specific NF-κB site. Recently, it was found that NF-κB differently
regulates Aβ production under physiological and supra-
physiological Aβ concentrations by modulating secretase
expression [30]. Under physiological conditions, NF-κB
lowers the transcriptional activity of BACE1 promoter and
triggers a repressive effect on Aβ production. However,
NF-κB activates the transcription of BACE1 promoter and
enhances Aβ production under pathological context. Thus,
using compounds to modulate BACE1 expression based
on NF-κB might lead to different outcomes under different
conditions.
HIF-1 is a hetero-dimeric transcription factor composed
of an oxygen-regulated alpha-subunit (HIF1α) and a con-
stitutively expressed and stable beta-subunit (HIF1β) [31].
Under hypoxic conditions, HIF-1 binds to a hypoxia-
responsive element (HRE) on a target gene promoter and
activates gene expression [32]. A functional HRE was
identified in human and mouse BACE1 gene promoter
[33,34]. Indeed, hypoxia augments β-secretase cleavage of
APP by increasing BACE1 gene transcription both in vivo
and in vitro. The effect of hypoxia on BACE1 expression
is presumably mediated by HIF-1α. Over-expression of
HIF-1α increased BACE1 mRNA and protein levels,
whereas down-regulation of HIF-1α reduced the level of
BACE1 expression. Consistent with these results, BACE1
expression was reduced in the hippocampus and the
cortex of HIF-1α conditional knock-out mice [34]. Add-
itionally, hypoxia treatment markedly increased Aβ depo-
sition and neuritic plaque formation and potentiated the
memory deficit in Swedish mutant APP transgenic mice
[33]. Recently, it was shown that hypoxia up-regulates
BACE1 expression through two distinct mechanisms: an
early release of reactive oxygen species from mitochondria
and a late activation of HIF-1α [35]. Interestingly, sali-
droside, which has long been used in traditional Tibetan
medicine to relieve high altitude sickness, is able to
attenuate Aβ accumulation via HIF-1α-mediated reduc-
tion of BACE1 expression [36]. The link between hypoxia
and BACE1 expression provides a molecular mechanism
for increased incidence of AD following cerebral ischemic
and stroke injuries.
Peroxisome proliferator-activated receptor-gamma
(PPARγ) is a ligand-activated nuclear transcription factor
that has two isoforms, PPARγ1 and PPARγ2 [37,38].
These isoforms are produced by alternative splicing of the
same gene. PPARγ can form heterodimers with retinoid X
receptors (RXR) and binds to PPAR-responsive element
(PPRE) upon ligand activation [39]. The BACE1 gene
promoter also contains PPRE and mutagenesis of the
PPRE increased BACE1 gene promoter activity by abo-
lishing PPARγ binding to PPRE [40]. Over-expression of
PPARγ has been shown to reduce BACE1 gene promoter
activity. These results suggest a repressive role of PPARγ
on BACE1 expression. Interestingly, brain extracts from
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to PPRE on the BACE1 gene promoter was decreased
[40]. Pro-inflammatory cytokines decrease PPARγ mRNA
level and this effect was suppressed by non-steroidal anti-
inflammatory drugs (NSAIDs). Intriguingly, NSAIDs were
shown to modulate BACE1 transcription by repressing its
promoter activity specifically through PPARγ [40]. Indeed,
epidemiological evidence suggests that a strong inflamma-
tory reaction is present in AD brains and long-term treat-
ments with NSAIDs decrease the risk for AD [41]. PPARγ
could be herein a major regulatory factor for modulating
inflammation. The activation of PPARγ by agonists such
as certain NSAIDs could open a prospective avenue for
AD therapy.
Transcription regulation of APOE
Apolipoprotein E (ApoE) is a major cholesterol carrier
in the brain [42,43]. ApoE is primarily produced by
astrocytes and its function is to deliver lipids to neurons
through the binding of cell surface ApoE receptors [44].
Human ApoE exists as three polymorphic alleles: ε2, ε3
and ε4 [43]. These three isoforms differ from each other
by a single amino acid, resulting in different protein struc-
tures, lipid association and receptor binding [45-47]. The
ε4 allele of the ApoE is the strongest genetic risk factor for
late-onset AD (LOAD) [48]. Individuals with one ε4 allele
are 3–4 times more likely to develop AD than those
without ε4 allele [49]. Interestingly, the rare ε2 allele
has a protective effect against AD compared with the
ε3 allele [50].
In addition to the polymorphisms at the ε2/ε3/ε4 locus,
changes in APOE expression level have been reported to
be associated with AD, although the results remain con-
troversial [51]. ApoE levels have been found to be increa-
sed in the cerebrospinal fluid (CSF), plasma and frontal
cortex of AD patients [52-54]. However, other studies
have observed either no change or a decrease in the ApoE
levels of AD patients [55-58]. Such discrepancies may be
related to confounding factors interfering with sample
handling and/or analyses, of which remains to be clarified.
Indeed, one study pinpointed that the hydrophobic
character of ApoE resulted in adsorption to different types
of test tubes commonly used for collection of CSF at
lumbar puncture, resulting in falsely low levels [58]. More
recently, two groups showed consistent results that redu-
cing human ApoE level attenuates amyloid deposition in
mutant human APP transgenic mouse model, regardless
of isoform status [59,60]. Thus, overall APOE expression
level plays an important role in AD pathology, although
the exact correlation remains controversial.
APOE expression is regulated by nutritional, develop-
mental and hormonal factors which bind to its proximal
promoter region [61-63]. In contrast to BACE1, the 5’-
flanking sequence of APOE harbors a functional TATAbox [64]. Multiple cis-acting positive and negative regu-
latory elements have been mapped to the 5'-flanking
sequence of APOE, including AP-2, PPARγ and liver X
receptor (LXR) [65-68].
AP-2 is an astrocyte-associated transcription factor
whose expression can be strongly and rapidly induced by
cyclic AMP (cAMP) [69]. Retinoic acid (RA) is also
known to regulate the transcriptional activity of AP-2
gene [70]. Interestingly, the activity of the proximal
APOE promoter in astrocytes is up-regulated by cAMP
and RA synergistically [65]. Sequence analysis and foot-
printing technique revealed the existence of two binding
sites for AP-2 in the APOE promoter which might
mediate the stimulatory effect of cAMP and RA [65].
Mutations in these regions markedly impaired the trans-
stimulatory effect of AP-2 on APOE expression [65].
These results indicate the existence of functional AP-2 sites
in the promoter region of ApoE. The AP-2 transcription
factor family consists of five isoforms (α, β, γ, δ and ε),
with α- and β-isoform abundantly expressed in the brain
[71,72]. Interestingly, a recent study observed that Aβ
induced a time-dependent increase in APOE mRNA in
astrocytes which was mediated by AP-2β [73]. The tran-
scriptional up-regulation of APOE level by Aβ may be a
neuro-protective response against Aβ-induced cytoto-
xicity, consistent with ApoE’s role in cytoprotection.
Proliferator-activated receptor gamma (PPARγ) and liver
X receptors (LXRs) form obligate hetero-dimers with ret-
inoid X receptors (RXRs) and are reported to regulate
APOE transcription [66,68]. Indeed, the LXR agonists
GW3965 and TO901317 were reported to increase APOE
expression in astrocytes, enhance Aβ clearance and ameli-
orate the memory deficit in amyloid mouse model [66,67].
Similar to LXRs, PPARγ agonists such as pioglitazone and
ciglitazone can also induce APOE expression and rescue
the behavioral deficits in AD mouse model [39,68]. In
addition, RXR activation by numerous compounds has
shown to increase APOE level, likely through activation of
RXR and PPAR signaling pathways [74,75]. Owing to their
ability to enhance APOE gene expression and promote Aβ
degradation, LXRs, PPARs, and perhaps RXRs, serve as an
attractive therapeutic target for AD.
While rarely-detected on the BACE1 gene promoter,
polymorphisms within the proximal promoter of the APOE
gene lead to changes in ApoE level by altering gene tran-
scription [76]. Four promoter polymorphisms have been
identified and their association with AD risk has been
investigated, including −491 (A/T transversion), −427 (T/C
transition), −219 (G/T transversion, also known as the
Th1/E47cs polymorphism), +113 (C/G transversion, also
termed IE1) [77-80]. These polymorphisms are proposed
to affect the transcriptional activity of ApoE gene by
altering the binding of transcription factors [81]. Among
them, the −491 A/T polymorphism has been the most
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level. The A to T substitution at −491, and the T to G
substitution at −219, resulted in a 63% decrease and a
169% increase of the APOE promoter activity, respectively
[81]. Epidemiological studies have shown that the −491 T
allele was associated with a decreased risk for AD, while
the −219 T allele was associated with an increased risk for
AD occurrence, independently of the ε2/ε3/ε4 polymor-
phism [82]. These data suggest that these promoter poly-
morphisms are functional in nature. In addition to the
polymorphism within the coding region, uncovering the
polymorphism within the APOE promoter might be also
beneficial to predict AD risk.
Transcription regulation of other AD genes
APP belongs to the type I transmembrane proteins,
encompassing a long extracellular domain, a hydropho-
bic transmembrane domain, and a short C-terminal
intracellular domain [6]. The human APP gene is located
on the long arm of chromosome 21 and contains at least
18 exons [83]. APP is abundantly expressed in the neur-
onal cells of the central nervous system; and the me-
chanisms controlling APP gene expression have been
extensively studied [8,84-88]. The APP promoter is
devoid of typical TATA and CAAT boxes, but contains a
strong initiator element surrounding the major tran-
scription start site [89]. The promoter sequences of APP
gene are highly conserved among species, and share
numerous binding sites for regulatory transcription
factors [85,86,90,91]. The APP promoter activation is
mainly governed by two GC-rich elements, the −93/−82
fragment (APBβ) which is bound by CCCTC-binding
factor (CTCF) and the −65/−41 fragment (APBα) which is
bound by stimulating protein 1 (SP1) and the upstream
stimulatory factor (USF) [92-96]. Further, numerous stress
factors could activate APP transcription which is mediated
by heat-shock factor 1 (HSF-1) binding to the heat-shock
element (HSE) at position −317 [97]. Another transcrip-
tion factor NF-κB was found to specifically recognize two
identical sequences at −2250/−2241 and −1837/−1822 on
APP promoter. In neural cells that were treated with
either the inflammatory cytokine interleukin-1beta (IL-1β)
or the excitatory amino-acid glutamate, NF-κB up-
regulated the transcriptional activity of the APP promoter
[98,99]. Rac1, a member of the Rho family GTPases, was
shown to stimulate the transcription of APP promoter in
the region between −233 and −41 bp [100]. In primary
hippocampal neurons, over-expression of the dominant-
negative Rac1 mutant or the presence of Rac1 inhibitors
decreased the levels of APP mRNA, indicting Rac1 could
be a potential drug target for AD therapy [100]. Other
regulatory elements includes the binding sites for activator
protein 1 (AP1), cAMP-responsive element-binding pro-
tein (CREB) and ‘GATA’ binding factor 1 (GATA1) [101].Interestingly, copper depletion significantly reduced APP
gene expression by acting on the region between −490
and +104 of APP promoter [102]. In addition, pro-
moter polymorphisms have been found to modulate
APP expression and therefore increase susceptibility to
AD, including −877 T/C, −955A/G [103].
Presenilin genes (PSEN1 and PSEN2) encode highly
homologous integral membrane proteins which are the
catalytic subunits of γ-secretase [104-106]. PSEN muta-
tions cause abnormal processing of APP and lead to
early onset AD [107-109]. Therefore, PSEN gene re-
gulation may play a crucial role in the development of
AD. Both PSENs are expressed primarily in neurons
[110,111]. Their promoters lack a TATA box but contain
transcriptionally active GC boxes [112,113]. To date,
most studies are focused on the transcriptional regula-
tion of PSEN1; little is known about the transcriptional
control of PSEN2. Deletion mapping of the human
PSEN1 promoter delineated the most active region
between −22 and −6 which controls over 90% of PSEN1
promoter activity [114]. Ets transcription factors bind to
this region and activate PSEN1 transcription [115]. Intri-
guingly, co-activator p300 appears to interact with Ets
transcription factors and co-activate PSEN1 transcription
[115]. Zinc finger protein (ZNF237) and chromodomain
helicase DNA-binding protein (CHD3) interact with Ets
transcription factor ERM and inhibit PSEN1 transcription
[116,117]. Since p300 has intrinsic histone acetyl-
transferase (HAT) activity and CHD3 is a component of
the histone deacetylase (HDACs) complex, chromatin
modification by acetylation and deacetylation may play a
critical role for PSEN1 transcription regulation [118]. In a
separate study, cAMP-responsive element-binding protein
(CREB) was shown to bind PSEN1 promoter upon stimu-
lation by N-Methyl-D-aspartate (NMDA) or brain-derived
neurotrophic factor (BDNF), and enhance PSEN1 tran-
scription [119]. Further, IL-1β and Aβ42 peptide syner-
gistically activated PSEN1 gene expression and the effect
could be enhanced by hypoxia. At least two promoter
polymorphisms (−22C/T, −48C/T) have been found to
modulate PSEN1 expression and AD risk [120,121]. On
the PSEN2 promoter, a functional nerve growth factor
(NGF) binds to its responsive element and leads to two-
fold up-regulation of PSEN2 transcription [122]. Early
growth response gene-1 (Egr-1) binds to PSEN2 promoter,
and PSEN2 level is increased three-fold by over-expression
of Egr-1, or by 12-O-tetradecanoylphorbol-13-acetate (TPA)
which increases Egr-1 level [123].
Recently, studies from two independent groups of
researchers suggested that rare variants in the TREM2
(triggering receptor expressed on myeloid cells 2) gene
are associated with an increased risk of late-onset AD
[124,125]. TREM2 encodes a single-pass type I mem-
brane receptor that regulates cell activity through a
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(also called DAP12) [126]. In the brain, TREM2 is domin-
antly expressed in microglia and performs two important
roles: suppresses inflammatory reactivity and mediates the
phagocytosis of cell debris [127,128]. Impaired function of
the TREM2 gene may therefore affect the inflammatory
processes and the clearance of amyloid plaques, ultimately
leading to increased risk for AD. Interestingly, TREM2
expression in microglia was reduced more than 8-fold
after Aβ treatment [129], which indicates that increasing
TREM2 level might be beneficial for AD therapy. Regula-
tion of TREM2 transcription especially in microglia re-
mains largely unknown. Identifying the transcriptional
regulators for TREM2 expression may therefore open a
new avenue for AD therapy.
Conclusions
This present review summarizes the mechanisms of tran-
scriptional regulation for several important AD genes and
their misregulation that leads to AD susceptibility. Mount-
ing evidence has emerged to support an important role of
transcription regulation in the initiation and progression
of AD. With a more thorough understanding of the
changes for the gene expression profile, reciprocal drug
targets can be developed to reverse the changes in tran-
scription and alleviate AD symptoms. In addition, an alter-
ation in gene expression presumably occurs in the early
stage of the disease and accounts for the appearance of
pathological hallmarks. Therefore, diagnostic techniques
based on gene expression changes have the potential to
detect the onset of AD before it is histologically obvious,
thus allowing early treatment to prevent disease onset and
provide long-lasting efficacy after discontinuation of the
treatment [130].
AD therapy based upon the modulation of gene expres-
sion profiles relies heavily on a comprehensive under-
standing of the regulatory transcription factors and their
responding elements on the promoter of AD genes. In
recent years, important progress has been made in under-
standing the transcription regulation of BACE1, APOE,
APP and PSEN promoters. The regulation of BACE1
promoter activity has been extensively studied and the
derived knowledge has been guiding the identification of
compounds to inhibit BACE1 expression through compre-
hensive drug screening. Regulation of APOE transcription
is only partially investigated in the central nervous system
and could be extremely complex. Human ApoE exists as
three polymorphic alleles: ε2, ε3 and ε4, special attention
needs to be drawn to mechanisms of differential expres-
sion of the different ApoE isoforms. Aβ peptide generation
depends largely on the amount of APP substrate. There-
fore, the regulation of APP transcription plays an im-
portant role in AD susceptibility. Several studies have
observed an increase of APP mRNA levels in AD brainswhich exacerbates Aβ deposition [8,131]. The up-regu-
lated levels of APP could be attributed to the altered bind-
ing of transcription factors to their specific positive and
negative cis-elements. Because presenilins are the catalytic
subunits of γ-secretase, drugs developed to inhibit the
transcription of PSENs could potentially reduce Aβ gene-
ration. However, presenilins cleave a large number of
trans-membrane targets (such as Notch), significant side
effects could be induced by down-regulating PSEN
transcription or enzymatic activity [132-134]. Better un-
derstanding of the transcriptional properties of PSENs in
the future could provide a mechanistic target to poten-
tially alleviate AD pathology; with minimal side effects.
Intriguingly, a recent study demonstrated that PSEN2, but
not PSEN1, plays an important role in mediating Notch
cleavage [135]. PSEN2-sparing γ-secretase inhibition was
suggested to a novel and efficacious γ-secretase targeting
strategy for AD. Therefore, transcription factors that spe-
cifically inhibit the expression of PSEN1, but not PSEN2,
would be an effective and novel drug target for AD
therapy. At this present time, researchers have also
focused on polymorphisms within the AD gene promoter,
since single-nucleotide changes have been documented to
affect transcriptional activity of AD genes. These poly-
morphisms may affect transcription factor binding either
by directly altering a transcription factor binding site, or
by changing the structure of DNA thereby affecting the
access of transcription factor to the binding site.
Recently, genome-wide expression studies have been
performed to investigate the complex pathogenesis of
AD by using transgenic AD animals, patient-derived cell
lines, and post-mortem brain tissues [136]. Changes in
the transcription levels of a group of genes have been
identified, although the results have been discordant, and
may be possibly due to different experimental approaches
used [136]. With the development of array technologies
especially the RNA-seq technique, more comprehensive
and accurate transcriptome analysis could be derived to
interpret the pathogenesis of AD. With the increasing
number of AD genes being discovered, further analysis of
the transcriptional regulation of these AD genes and the
variants in their regulatory regions will not only help to
elucidate AD etiology, but also guide targeted drug devel-
opment for AD therapy.
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